Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-28 pm EDT 		Pre-market 07:59:42 pm
40.49 USD -1.82% Intraday chart for Bristol-Myers Squibb Company 40.52 +0.07%
May. 28 Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License MT
May. 27 Bristol Myers: will present data on schizophrenia CF

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
BU
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
BU
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab
AQ
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
BU
Hawaii court orders drug companies to pay $916 million in Plavix blood thinner lawsuit
AQ
Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign
BU
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
BU
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
BU
Bristol Myers Squibb : Transcript
PU
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BU
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BU
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BU
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
BU
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
BU
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
PR
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BU
Bristol Myers Squibb : Q1 2024 Results Presentation (with Appendix)
PU
Bristol Myers: Q1 Earnings Snapshot
AQ
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BU
Bristol Myers Squibb : Preliminary Q1 2024 Acquired IPRD and Licensing Income Schedule
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company
  5. Press Releases